<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9319162</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2572</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Opin Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Opin. Neurol.</journal-id>
<journal-title-group>
<journal-title>Current opinion in neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1350-7540</issn>
<issn pub-type="epub">1473-6551</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26844621</article-id>
<article-id pub-id-type="pmc">4798424</article-id>
<article-id pub-id-type="doi">10.1097/WCO.0000000000000300</article-id>
<article-id pub-id-type="manuscript">NIHMS767280</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Considerations in biomarker development for neurodevelopmental disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>McPartland</surname>
<given-names>James C.</given-names>
</name>
<degrees>Ph.D.</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="CR1">Correspondence to: James C. McPartland, Ph.D., Yale Child Study Center, 230 South Frontage Road, New Haven, CT 06520, <email>james.mcpartland@yale.edu</email>, (203) 785-7179</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2017</year>
</pub-date>
<volume>29</volume>
<issue>2</issue>
<fpage>118</fpage>
<lpage>122</lpage>
<!--elocation-id from pubmed: 10.1097/WCO.0000000000000300-->
<abstract>
<sec id="S1">
<title>Purpose of review</title>
<p id="P1">Despite significant progress in recognizing the biological bases of autism spectrum disorder, diagnosis and treatment rely primarily on subjective evaluation of behavior. This review highlights the challenges unique to neurodevelopmental disorders that have limited biomarker development.</p>
</sec>
<sec id="S2">
<title>Recent findings</title>
<p id="P2">The field of neurodevelopmental disorders requires objective quantification of biological processes to enable designation of subgroups likely to benefit from specific treatments, index diagnostic status/risk, demonstrate engagement of targeted systems, and provide more rapid assessment of change than traditional clinical observation and caregiver report measures.</p>
</sec>
<sec id="S3">
<title>Summary</title>
<p id="P3">Useful biomarkers for neurodevelopmental disorders must be reliable across development, evident at the individual level, and specific to a unit of analysis, be it diagnostic status or functional process. The ultimate value of biomarkers for neurodevelopmental disorders will relate to their ease of use, cost, scalability, sensitivity, and methodological objectivity.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Autism Spectrum Disorder</kwd>
<kwd>Neurodevelopmental Disorders</kwd>
<kwd>Biomarkers</kwd>
<kwd>EEG</kwd>
<kwd>ERP</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>